Regeneron Pharmaceuticals (REGN) Non-Current Deffered Revenue (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Non-Current Deffered Revenue of $220.4 million for Q2 2026, up 6.83% year-over-year from $206.3 million in Q2 2025, and down 2.09% quarter-over-quarter from $225.1 million in Q1 2026.
Regeneron Pharmaceuticals (REGN) Non-Current Deffered Revenue (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Non-Current Deffered Revenue history runs 18 years deep, the most recent figure standing at $220.4 million for Q2 2026.
- In Q2 2026, Non-Current Deffered Revenue rose 6.83% year-over-year to $220.4 million; the TTM figure through Jun 2026 stood at $220.4 million (up 6.83% YoY), while the FY2025 annual figure was $208.7 million, up 12.39% from the prior year.
- Non-Current Deffered Revenue for Q2 2026 stood at $220.4 million, down from $225.1 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $225.1 million in Q1 2026, with the low at $33.5 million in Q1 2022.
- The 5-year median for Non-Current Deffered Revenue is $185.8 million (2024), against an average of $152.9 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue slipped 4.77% in 2022, then soared 155.22% in 2023.
- Regeneron Pharmaceuticals' Non-Current Deffered Revenue stood at $69.8 million in 2022, then soared by 81.52% to $126.7 million in 2023, then surged by 46.57% to $185.7 million in 2024, then grew by 12.39% to $208.7 million in 2025, then increased by 5.61% to $220.4 million in 2026.
- Business Quant data shows REGN's Non-Current Deffered Revenue at $220.4 million in Q2 2026, $225.1 million in Q1 2026, and $208.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 220.40 Mn |
| Mar 31, 2026 | 225.10 Mn |
| Dec 31, 2025 | 208.70 Mn |
| Sep 30, 2025 | 219.20 Mn |
| Jun 30, 2025 | 206.30 Mn |
| Mar 31, 2025 | 211.80 Mn |
| Dec 31, 2024 | 185.70 Mn |
| Sep 30, 2024 | 207.40 Mn |
| Jun 30, 2024 | 205.60 Mn |
| Mar 31, 2024 | 185.80 Mn |
| Dec 31, 2023 | 126.70 Mn |
| Sep 30, 2023 | 125.30 Mn |
| Jun 30, 2023 | 116.20 Mn |
| Mar 31, 2023 | 85.50 Mn |
| Dec 31, 2022 | 69.80 Mn |
| Sep 30, 2022 | 60.10 Mn |
| Jun 30, 2022 | 58.70 Mn |
| Mar 31, 2022 | 33.50 Mn |
| Dec 31, 2021 | 73.30 Mn |
| Sep 30, 2021 | 56.50 Mn |